Avantor, Inc. · NYSE:AVTR
Avantor — Q2 2025 Earnings Presentation
9 slides from Avantor's earnings presentation, Aug 1, 2025
Slide 1: Q2 2025 Earnings Presentation
Q2 2025 Earnings Earnings Presentation August 1, 2025
Slide 2: Disclaimer
Disclaimer Forward-looking statements Non-GAAP financial measures This presentation contains forward-looking statements within the meaning of Section To evaluate our performance, we monitor a number of key indicators at the 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Slide 3: Q2 2025 performance highlights
Laboratory Solutions: Q2 2025 performance highlights • Sequential growth driven by actions to protect and grow share • Significant contract expansions / extensions, Reported Adjusted including 5-year BIO contract extension Revenue1 EBITDA margin • Launched digital suite of tools & pricing optimizati
Slide 4: Q2'25 financial results
Q2’25 financial results Q2’25 Q2’24 Reported revenue $1,683M Organic growth Flat Adj. gross profit $554M % of revenues 32.9% Adj. EBITDA $280M % of revenues 16.6% Adj. operating income $252M % of revenues 15.0% Adj. earnings per share $0.24 Free cash flow1 $125M Adj. net leverage2 3.2x 1Free Cash Fl
Slide 5: Q2'25 performance by segment
Q2’25 performance by segment Laboratory Solutions Bioscience Production Reported Adjusted Reported Adjusted Revenue Operating income Revenue Operating income $1,122M $133M $561M $140M Adjusted Adjusted Organic Growth: -1% Operating 11.9% Organic Growth: 2% Operating 24.9% Margin: Margin: Note: Page
Slide 6: 2025 full-year guidance
2025 full-year guidance1,2 -1% to +1% -2% to 0% 17.5% to 18.5% 16.5% to 17.0% $1.02 to $1.10 $0.94 to $0.98 4 $650 to $700M $550 to $600M 1For reconciliation from impact of Clinical Services divestiture, see Appendix 2Reported revenue range is -3% to -1%, reflecting 1% FX tailwind and a 2% headwind
Slide 7: Powering science at every step.
Powering science at every step.
Slide 8: Appendix
Appendix 8 // Confidential & Proprietary
Slide 9: Clinical Services divestiture impact
Clinical Services divestiture impact1,2,3 SECOND QUARTER IMPACT ~$48M ~$17M ~$0.01 ~$7M Reported revenue Adjusted EBITDA Adjusted EPS Free cash flow headwind headwind dilution headwind Reported YoY Growth Adj. EBITDA Margin Net Interest Expense Headwind ~2.8% Headwind ~50bps Reduction $7M FULL YEAR